prikaz prve stranice dokumenta Važnost antagonista mineralokortikoidnih receptora u terapiji rezistentne hipertenzije
  Download
PDF 383.94 KB
master's thesis
Važnost antagonista mineralokortikoidnih receptora u terapiji rezistentne hipertenzije
Zagreb: University of Zagreb, School of Medicine, 2016. urn:nbn:hr:105:362511
Legović, Ana
University of Zagreb
School of Medicine
Department of Internal Medicine

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Legović, A. (2016). Važnost antagonista mineralokortikoidnih receptora u terapiji rezistentne hipertenzije (Master's thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:362511

Legović, Ana. "Važnost antagonista mineralokortikoidnih receptora u terapiji rezistentne hipertenzije." Master's thesis, University of Zagreb, School of Medicine, 2016. https://urn.nsk.hr/urn:nbn:hr:105:362511

Legović, Ana. "Važnost antagonista mineralokortikoidnih receptora u terapiji rezistentne hipertenzije." Master's thesis, University of Zagreb, School of Medicine, 2016. https://urn.nsk.hr/urn:nbn:hr:105:362511

Legović, A. (2016). 'Važnost antagonista mineralokortikoidnih receptora u terapiji rezistentne hipertenzije', Master's thesis, University of Zagreb, School of Medicine, accessed 22 November 2024, https://urn.nsk.hr/urn:nbn:hr:105:362511

Legović A. Važnost antagonista mineralokortikoidnih receptora u terapiji rezistentne hipertenzije [Master's thesis]. Zagreb: University of Zagreb, School of Medicine; 2016 [cited 2024 November 22] Available at: https://urn.nsk.hr/urn:nbn:hr:105:362511

A. Legović, "Važnost antagonista mineralokortikoidnih receptora u terapiji rezistentne hipertenzije", Master's thesis, University of Zagreb, School of Medicine, Zagreb, 2016. Available at: https://urn.nsk.hr/urn:nbn:hr:105:362511

Metadata
TitleVažnost antagonista mineralokortikoidnih receptora u terapiji rezistentne hipertenzije
Title (english)The importance of mineralocorticoid receptor antagonists n the treatment of resistant hypertension
AuthorAna Legović
MentorIngrid Prkačin (mentor)
Committee memberNikolina Bašić Jukić (predsjednik povjerenstva)
Committee memberJasenka Markeljević (član povjerenstva)
Committee memberIngrid Prkačin (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Zagreb
Defense date and country2016-07-15, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract
Prevalencija rezistentne hipertenzije (RH) se kreće između 10-30%, a povezana je s višim rizikom oštećenja bubrega i kardiovskularnog sustava. Patofiziologija RH je povezana s povišenom razinom aldosterona zbog čega antagonisti mineralokortikoidnih receptora (MRA) u terapiji igraju važnu ulogu. Aldosteron je hormon nadbubrežne žlijezde koji se stvara i izlučuje na poticaj angiotenzina II, adrenokortikotropnog hormona (ACTH) i kalija. Vezanjem za mineralokortikoidne receptore (MR) potiče transkripciju i ekspresiju natrijevih kanala (ENaC) koji resorbiraju natrij, a radi osmotske ravnoteže resorbira se i voda i time dolazi do hipervolemije i hipertenzije. U više istraživanja, među kojima je najvažnije PATHWAY-2, je dokazano da spironolakton kao dodatak na inicijalnu trojnu terapiju (blokatori renin-angiotenzin sustava, diuretici i blokatori kalcijevih kanala) snizuje sistolički krvni tlak <135mmHg u 60% pacijenata. Osim spironolaktona, isti učinak ima i drugi lijek skupine MRA, eplerenon. Prije propisivanja ovih lijekova, važno je procijeniti bubrežnu funkciju pacijenata zbog mogućeg rizika od hiperkalijemije.
Abstract (english)
The prevalence of resistant hypertension ( RH ) is ranging between 10-30 % , and is associated with a higher risk of kidney and cardiovascular system damage. Pathophysiology of RH is associated with increased levels of aldosterone and because of that, antagonists of mineralocorticoid receptors play significant role in therapy. Aldosterone is an adrenal hormone which is produced and secreted on the stimulus of angiotensin II, adrenocortical hormone (ACTH) and potassium. It stimulates transcription and expression of sodium channels (ENaC) by binding to mineralocorticoid receptors (MR). These channels absorb sodium, and because of osmotic balance, water is absorbed too thus causing hypervolemia and hypertension. There have been many researches, in which PATHWAY-2 is the most important, that prove adding spironolactone to initial therapy (renine-angiotensine blockers, diuretics and calcium channel blockers) lowers systolic blood pressure <135mmHg in 60% of patients. Except spironolactone, the same effect has another drug from MRA group, eplerenone. Before prescribing these drugs, it is important to evaluate renal function because of possible risk of hyperkalemia.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:105:362511
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2017-06-26 07:34:35